Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

SARS-CoV-2 mutations allow escape from clinical monoclonal antibodies

A new research paper recently uploaded to the preprint server bioRxiv by Jesse D. Bloom et al. (22nd Feb 2021) aims to map all of the currently circulating SARS-CoV-2 lineages with resistance towards LY-CoV555 and LY-CoV016, and document the specific mutations that confer resistance, ultimately suggesting that future monoclonal antibody cocktails should target a more diverse range of epitopes.

23 Feb 2021

Could laser-facilitated epicutaneous vaccination for SARS-CoV-2 be an alternative to intramuscular injection?

Scientists at the University of Salzburg and Pantec Biosolutions AG have developed a laser-facilitated epicutaneous immunization against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. The model has induced angiotensin-converting enzyme 2 (ACE2) blocking antibodies in mice.

23 Feb 2021

Protective COVID-19 antibodies can transfer from mothers to babies in the womb

Antibodies that guard against COVID-19 can transfer from mothers to babies while in the womb, according to a new study from Weill Cornell Medicine and NewYork-Presbyterian researchers published in the American Journal of Obstetrics and Gynecology.

23 Feb 2021

Influenza A virus defective interfering particles against SARS-CoV-2

In the search for a broadly acting pan-specific antiviral, an interdisciplinary team from Germany tested the previously proposed (for antiviral treatment against Influenza A infections) - Influenza A virus (IAV) defective interfering particles (DIPs). The research is published online on the bioRxiv preprint server.

23 Feb 2021

In vivo imaging reveals how anti-CD20 antibodies guide the immune system to attack tumors

Monoclonal antibodies are part of the therapeutic arsenal for eliminating cancer cells. Some make use of the immune system to act and belong to a class of treatment called "immunotherapies." But how do these antibodies function within the tumor? And how can we hope to improve their efficacy?

22 Feb 2021

Virus-specific cellular immunity may be essential for long-term protection against SARS-CoV-2

Researchers from China and the US recently synthesized select peptide pools of the structural and functional proteins of SARS-CoV-2, including spike (S), envelope (E), membrane (M), nucleocapsid (N), and protease (P) proteins as target antigens to assess COVID-19-specific immunity.

22 Feb 2021

Seropositive individuals show similar antibody levels to a second mRNA vaccine dose

Seropositive individuals —people who received antibodies after COVID-19 infection — may be able to safely delay their second mRNA vaccine dose after all, according to the results of a new study.

22 Feb 2021

Current monoclonal antibodies less potent against SARS-CoV-2 variants

Researchers at the New York University Grossman School of Medicine and Biohaven Pharmaceuticals found that the REGN10933 and REGN10987 combination was 9.1-fold less potent on the B.1.351 variant, which emerged in South Africa, and 16.2-fold less potent on mink cluster 5.

22 Feb 2021

FDA issues guidance for medical product developers to address the emergence of SARS-CoV-2 variants

Today, the U.S. Food and Drug Administration issued guidances for medical product developers, specifically covering vaccines, diagnostics and therapeutics products, to address the emergence and potential future emergence of variants of SARS-CoV-2, the virus that causes COVID-19.

22 Feb 2021

An overview of spike protein antigen COVID-19 vaccine candidates

A new paper in the journal Reviews in Medical Virology provides a perspective on current vaccine development strategies and tools, which may allow the production of safe and effective vaccines.

22 Feb 2021

COVID-19 vaccine candidate shows potential against SARS-CoV-2 and potential future zoonotic coronaviruses

A new study sheds light on the threat posed by future zoonotic coronaviruses to make similar leaps across species barriers to infect human beings and cause other pandemics.

22 Feb 2021

Study profiles the nose to predict immune response during COVID-19

SARS-CoV-2 resides in mucous membranes, making it easy to detect viral load in the nasal cavities. An international group of researchers has characterized the immunological and diagnosis characteristics of patients who may have or are confirmed with SARS-CoV-2 infection. The team found a distinct nasal cytokine profile that could help identify patients at risk for high inflammatory responses to SARS-CoV-2 infection.

22 Feb 2021

Some SARS-CoV-2 variants evade mRNA vaccine-induced humoral immune, says study

Understanding how variants escape vaccine-boosted immune function is necessary to neutralizing SARS-CoV-2. An international team of researchers from MIT and Harvard University in the USA analyzed Pfizer and Moderna vaccines' effectiveness in neutralizing spike proteins from 10 different strains of SARS-CoV-2.

22 Feb 2021

Could an intranasal adjuvant to vaccines boost immunity against SARS-CoV-2 variants?

A research team from the University of Michigan Medical School, USA, developed a supplementary intranasal treatment to improve COVID-19 vaccine response and its effects on long-lasting immunity from other variants, such as the B.1.351 variant first found in South Africa.

22 Feb 2021

SARS-CoV-2 DNA vaccine tested in animal model

A team of experts has tested the immune responses elicited by mucosal homologous plasmid and a heterologous immunization strategy using a plasmid vaccine and a Modified Vaccinia Ankara (MVA) expressing SARS-CoV-2 spike (S) and nucleocapsid (N) antigens.

21 Feb 2021

Novel SARS-CoV-2 vaccine utilizes recombinant spike protein with PIKA adjuvant

The primary aim of any vaccine is to stimulate immune functions and confer long-lasting protection. A paper recently uploaded to the preprint server bioRxiv by Tong et al. (17th Feb 2021) describes a novel vaccine utilizing PIKA adjuvant and recombinant spike proteins against COVID-19 disease that promises the generation of potent neutralization antibodies, which potentially support immune responses for years.

21 Feb 2021

Interval between doses of Oxford COVID-19 vaccine can be safely extended to 3 months, suggests study

A 3-month interval between doses of the Oxford COVID-19 vaccine results in higher vaccine efficacy than a 6-week interval, with the first dose offering 76% protection in the 3 months between doses.

20 Feb 2021

Review provides an overview of immunogenicity profiles of leading SARS-CoV-2 vaccine candidates

In a new Review, P.J. Klasse and colleagues present an extensive overview of the immunogenicity profiles of several leading SARS-CoV-2 vaccine candidates, including several developed under the auspices of the U.S. Government's "Operation Warp Speed" program, as well as leading candidates from China and Russia.

20 Feb 2021

Intranasal COVID-19 vaccine candidate preclinically tested at UAB expected to start clinical trial

The Altimmune Inc. vaccine candidate that was tested preclinically at the University of Alabama at Birmingham last year is expected to start patient enrollment for its Phase 1 clinical trial next week.

20 Feb 2021

Live attenuated SARS-CoV-2 vaccine candidate shows protective efficacy in vivo

A new preprint on the bioRxiv* server describes the development of a live attenuated vaccine candidate to counter the growing threat of the COVID-19 pandemic.

19 Feb 2021

Antibody News and Research

Further Reading

SARS-CoV-2 mutations allow escape from clinical monoclonal antibodies

Could laser-facilitated epicutaneous vaccination for SARS-CoV-2 be an alternative to intramuscular injection?

Protective COVID-19 antibodies can transfer from mothers to babies in the womb

Influenza A virus defective interfering particles against SARS-CoV-2

In vivo imaging reveals how anti-CD20 antibodies guide the immune system to attack tumors

Virus-specific cellular immunity may be essential for long-term protection against SARS-CoV-2

Seropositive individuals show similar antibody levels to a second mRNA vaccine dose

Current monoclonal antibodies less potent against SARS-CoV-2 variants

FDA issues guidance for medical product developers to address the emergence of SARS-CoV-2 variants

An overview of spike protein antigen COVID-19 vaccine candidates

COVID-19 vaccine candidate shows potential against SARS-CoV-2 and potential future zoonotic coronaviruses

Study profiles the nose to predict immune response during COVID-19

Some SARS-CoV-2 variants evade mRNA vaccine-induced humoral immune, says study

Could an intranasal adjuvant to vaccines boost immunity against SARS-CoV-2 variants?

SARS-CoV-2 DNA vaccine tested in animal model

Novel SARS-CoV-2 vaccine utilizes recombinant spike protein with PIKA adjuvant

Interval between doses of Oxford COVID-19 vaccine can be safely extended to 3 months, suggests study

Review provides an overview of immunogenicity profiles of leading SARS-CoV-2 vaccine candidates

Intranasal COVID-19 vaccine candidate preclinically tested at UAB expected to start clinical trial

Live attenuated SARS-CoV-2 vaccine candidate shows protective efficacy in vivo

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo